Immune Cell Infiltration As an Indicator of the Immune Microenvironment of Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Feb 7

PMID 23385730

Citations 499

Authors

Y Ino

R Yamazaki-Itoh

K Shimada

M Iwasaki

T Kosuge

Y Kanai

N Hiraoka

Affiliations

Soon will be listed here.

Abstract

Background: The host immune reaction is represented by immune/inflammatory cell infiltrates. Here we systematically analysed tumour-infiltrating immune/inflammatory cells in pancreatic ductal carcinoma (PDC) and evaluated their clinicopathological impact.

Methods: Using immunohistochemistry, we examined tumour-infiltrating CD68(+) pan-macrophages, HLA-DR(+)CD68(+) M1 macrophages (M1), CD163(+) or CD204(+) M2 macrophages (M2), CD66b(+) neutrophils (Neu), CD4(+) T cells (CD4(+)T), CD8(+) T cells (CD8(+)T), and FOXP3(+)CD4(+) regulatory T cells (Treg) in 212 cases of PDC, and conducted correlation and survival analyses using the Kaplan-Meier method and Cox proportional hazards model.

Results: Higher levels of tumour-infiltrating pan-macrophages, M2, Neu, or the ratio of Tregs to CD4(+)T (%Treg) were significantly associated with shorter survival, whereas higher levels of tumour-infiltrating CD4(+)T, CD8(+)T, or the ratio of M1 to pan-macrophages (%M1) were significantly associated with longer survival. Survival analysis of pairs of these variables revealed that some of the resulting patient groups had exclusively longer survival. We then connected the apparently related factors, and two significant variables emerged: tumour-infiltrating CD4(+)T(high)/CD8(+)T(high)/%Treg(low) and tumour-infiltrating %M1(high)/M2(low). Multivariate survival analysis revealed that these variables were significantly correlated with longer survival and had a higher hazard ratio.

Conclusion: Tumour-infiltrating CD4(+)T(high)/CD8(+)T(high)/%Treg(low) and %M1(high)/M2(low) are independent prognosticators useful for evaluating the immune microenvironment of PDC.

Citing Articles

Photodynamic priming with red light triggers adaptive immune responses in a pancreatic cancer mouse model.

De Silva P, Saad M, Swain J, Mai Z, Kidd M, Choe J J Photochem Photobiol B. 2025; 265:113126.

PMID: 40007355 PMC: 11895200. DOI: 10.1016/j.jphotobiol.2025.113126.

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.

Sherpally D, Manne A Cancers (Basel). 2025; 17(4).

PMID: 40002184 PMC: 11853216. DOI: 10.3390/cancers17040589.

Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone.

Yagi T, Kagawa S, Nogi S, Taniguchi A, Yoshimoto M, Suemori K Cancer Immunol Immunother. 2025; 74(3):96.

PMID: 39904796 PMC: 11794937. DOI: 10.1007/s00262-025-03946-z.

Loss of increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration.

Kannen V, Rasmussen M, Das S, Giuliana P, Izzati F, Choksi H Front Immunol. 2025; 15:1513595.

PMID: 39867896 PMC: 11759301. DOI: 10.3389/fimmu.2024.1513595.

Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7.

Mochida Y, Ohuchida K, Zhang B, Yamada Y, Tsutsumi C, Kubo A J Cancer Res Clin Oncol. 2025; 151(2):45.

PMID: 39856454 PMC: 11761478. DOI: 10.1007/s00432-025-06095-z.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

Mosser D, Edwards J . Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-69. PMC: 2724991. DOI: 10.1038/nri2448. View

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T . CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004; 28(1):e26-31. DOI: 10.1097/00006676-200401000-00023. View

Corzo C, Condamine T, Lu L, Cotter M, Youn J, Cheng P . HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010; 207(11):2439-53. PMC: 2964584. DOI: 10.1084/jem.20100587. View

Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F . Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2009; 167(2):e211-9. DOI: 10.1016/j.jss.2009.05.026. View

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A . Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11):549-55. DOI: 10.1016/s1471-4906(02)02302-5. View

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

Fridlender Z, Sun J, Kim S, Kapoor V, Cheng G, Ling L . Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell. 2009; 16(3):183-94. PMC: 2754404. DOI: 10.1016/j.ccr.2009.06.017. View

10.

Ferrone C, Dranoff G . Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010; 28(26):4045-51. PMC: 4872327. DOI: 10.1200/JCO.2010.27.9992. View

11.

Sica A, Mantovani A . Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122(3):787-95. PMC: 3287223. DOI: 10.1172/JCI59643. View

12.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S . Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12(18):5423-34. DOI: 10.1158/1078-0432.CCR-06-0369. View

13.

Komohara Y, Ohnishi K, Kuratsu J, Takeya M . Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008; 216(1):15-24. DOI: 10.1002/path.2370. View

14.

Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C . Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res. 2003; 63(6):1405-12. View

15.

Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T . Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010; 103(7):1057-65. PMC: 2965866. DOI: 10.1038/sj.bjc.6605854. View

16.

Filipazzi P, Huber V, Rivoltini L . Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2011; 61(2):255-263. PMC: 11029611. DOI: 10.1007/s00262-011-1161-9. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

19.

Rodriguez P, Ochoa A . Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008; 222:180-91. PMC: 3546504. DOI: 10.1111/j.1600-065X.2008.00608.x. View

20.

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View